Alcohol consumption at hazardous levels is associated with negative consequences on nearly every step of the HIV care continuum. It is a critical factor in HIV treatment that, if unaddressed, significantly contributes to onward transmission and poor treatment outcomes. Alcohol interventions for people living with HIV (PLWH) in the United States (US) have shown mixed results, and no alcohol intervention for PLHW has shown long-term reductions in heavy drinking or a significant impact on HIV-related outcomes. One hypothesized reason for this limited success is the failure of these interventions to address the multiple overlapping problems (e.g., comorbid mental health conditions, behavioral health needs) of PLWH who are hazardous drinkers. Innovative alcohol intervention strategies that can have an impact on these multiple behavioral health needs, in a format that can be feasibly delivered in the context of HIV care, are needed. Brief Acceptance and Commitment Therapy (ACT) is a promising intervention for HIV-infected hazardous drinkers. ACT is a transdiagnostic treatment that uses mindfulness skills and values-guided behavioral action plans to impact a broad array of psychological symptoms. ACT has shown efficacy for treatment of anxiety, depression, chronic pain, and substance use, making it a promising approach for hazardous drinkers. The overall objective of this application is to adapt an existing brief ACT intervention developed for smoking cessation, and pilot test its feasibility and acceptability for PLWH who are hazardous drinkers. We hypothesize that the resulting intervention will be preliminarily associated with decreased alcohol use, improved ART adherence, decreased symptoms of depression, anxiety, and drug use, and increased acceptance-a known mechanism of change in ACT.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Drinking Days: Baseline (at Baseline)
Timeframe: Baseline
Number of Drinking Days: Post-Treatment (at 7-weeks Post-baseline)
Timeframe: Post-treatment (at 7-weeks post-baseline)
Number of Drinking Days: 3-months (at 3-months Post-baseline)
Timeframe: 3-months post-baseline
Number of Drinking Days: 6-months (at 6-months Post-baseline)
Timeframe: 6-months post-baseline
Number of Drinks Per Drinking Day: Baseline (at Baseline)
Timeframe: Baseline
Number of Drinks Per Drinking Day: Post-Treatment (at 7-weeks Post-baseline)
Timeframe: Post-Treatment (7-weeks post-baseline)
Number of Drinks Per Drinking Day: 3-months (at 3-months Post-baseline)
Timeframe: 3-months post-baseline
Number of Drinks Per Drinking Day: 6-months (at 6-months Post-baseline)
Timeframe: 6-months post-baseline
Alcohol Consumption Measured by Phosphatidylethanol (PEth): Baseline (at Baseline)
Timeframe: Baseline
Alcohol Consumption Measured by Phosphatidylethanol (PEth): 6-months (at 6-months Post-baseline)
Timeframe: 6-months post-baseline
ART Adherence Measured by Self-Report: Baseline (at Baseline)
Timeframe: Baseline (at baseline)
ART Adherence Measured by Self-report: Post-treatment (at 7-weeks Post-baseline)
Timeframe: Post-treatment (at 7-weeks post-baseline)
ART Adherence Measured by Self-report: 3-months (at 3-months Post-baseline)
Timeframe: 3-months post-baseline
ART Adherence Measured by Self-report: 6-months (at 6-months Post-baseline)
Timeframe: 6-months post-baseline
ART Adherence Measured by Hair: Baseline
Timeframe: At Baseline
ART Adherence Measured by Hair: 6-months (6-months Post-baseline)
Timeframe: 6-months post baseline